Skip to content

Ketamine for depression: all studies

Page 129 of 154: studies 1,281 to 1,290 of 1,534, newest first. Back to the ketamine for depression overview

Research

Role of Ketamine in Refractory Depression

Telangana Journal of IMA 2021 Kolluri Maithri, Podalakuru Sandeep, Kota Suresh Kumar

Context: Refractory depression is seen in at least 10 to 30 percent of the patients suffering from depression. Ketamine is a new and effective option with rapid onset of action. But there are limited studies where IM Ketamine was used for treating refractory depression. Hence, this study is aimed at assessing the efficacy of IM Ketamine in patients with refractory depressionAims: To assess the...

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Therapeutic Advances in Psychopharmacology 2021 Adam Włodarczyk, Wiesław Jerzy Cubała, Maria Gałuszko‐węgielnik et al. 8 citations

Background: There is evidence supporting the use of ketamine in treatment-resistant depression (TRD). However, there are some safety and tolerability concerns associated with ketamine. This study aimed to investigate ketamine’s safety and tolerability to the central nervous system and to assess the relationship between dissociative symptomology and psychometric outcomes during and after...

Peripheral biomarkers in Repeated Ketamine Infusions Trial

2021 Amanda van Geel

Abnormalities in the endocrine and immune systems are well documented in patients with Major Depressive Disorder (MDD), however, the mechanisms by which the novel antidepressant treatment, ketamine, influences these physiological systems are unclear. This study examined the effects of repeated ketamine infusions on the endocrine and immune systems using the peripheral biomarkers C-reactive...

Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences

BJPsych Open 2021 Karen Lascelles, Lisa Marzano, Fiona Brand et al. 20 citations

BackgroundKetamine has recently received considerable attention regarding its antidepressant and anti-suicidal effects. Trials have generally focused on short-term effects of single intravenous infusions. Research on patient experiences is lacking.AimsTo investigate the experiences over time of individuals receiving ketamine treatment in a routine clinic, including impacts on mood and...

A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression.

Frontiers in Psychiatry 2021 Georgios Mikellides, Panayiota Michael, Lilia Psalta et al. 17 citations

Depression is a common mental disorder that affects many people worldwide, while a significant proportion of patients remain non-responsive to antidepressant medications. Alternative treatment options such as ketamine therapy and repetitive transcranial magnetic stimulation (rTMS) therapy are offered nowadays. This study aims to describe and compare the acute antidepressive efficacy of both,...

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

Psychotherapy and Psychosomatics 2021 Samuel t. Wilkinson, Taeho greg Rhee, Jutta Joormann et al. 102 citations

<b><i>Introduction:</i></b> Ketamine has emerged as a rapid-acting antidepressant. While ongoing treatment can prevent relapse, concerns exist regarding long-term exposure. <b><i>Objective:</i></b> We conducted a randomized trial to examine the feasibility and efficacy of cognitive behavioral therapy (CBT) following intravenous ketamine in treatment-resistant depression (TRD)....

Functional Dysconnectivity of Frontal Cortex to Striatum Predicts Ketamine Infusion Response in Treatment-Resistant Depression.

The International Journal of Neuropsychopharmacology December 29, 2020 Mu-Hong Chen, Wan-Chen Chang, Wei-Chen Lin et al. 28 citations

Frontostriatal disconnectivity plays a crucial role in the pathophysiology of major depressive disorder. However, whether the baseline functional connectivity of the frontostriatal network could predict the treatment outcome of low-dose ketamine infusion remains unknown. In total, 48 patients with treatment-resistant depression were randomly divided into 3 treatment groups (a single-dose...

DOI: 10.1093/ijnp/pyaa056 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Frontostriatal network Low-dose ketamine infusion Treatment response

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

HRB Open Research December 16, 2020 Bronagh Gallagher, Meabh Foley, C. Slattery et al. 6 citations

Background: Depression is a common psychiatric disorder that has become the leading cause of disability worldwide. The standard medical care for depression over the past 50 years has focused on monoamine neurotransmitters. These treatments can take weeks to take effect, highlighting the need for novel treatment strategies. One such approach may be ketamine. Ketamine acts as an antagonist of the...

The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.

Journal of Psychiatric Research December 11, 2020 Jiaqi Xiong, Orly Lipsitz, David C J Chen-Li et al. 122 citations

The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported. We aimed to evaluate acute anti-SI effects of single-dose ketamine in different formulations/routes of administration by pooling results from randomized controlled trials (RCTs). A systematic search was conducted on Cochrane, Embase, Medline, and PubMed from inception to July 1st, 2020. Studies were...

Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression

Brain Sciences December 11, 2020 Jakub Słupski, Wiesław Jerzy Cubała, Natalia Górska et al. 7 citations

Changes in serum copper concentration are observed in patients with depressive symptoms. Unmet needs in contemporary antidepressant treatment have increased interest in non-monoaminergic antidepressants, such as ketamine, an anaesthetic drug that has demonstrated a rapid antidepressant effect in patients with treatment-resistant depression (TRD). The purpose of this study was to examine whether...